AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 237 filers reported holding AMICUS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $352,423 | +19.4% | 24,836 | +2.3% | 0.00% | 0.0% |
| Q3 2023 | $295,075 | -22.1% | 24,286 | -19.6% | 0.00% | 0.0% |
| Q2 2023 | $378,872 | +59.9% | 30,189 | +41.3% | 0.00% | 0.0% |
| Q1 2023 | $237,004 | +6.9% | 21,371 | +17.7% | 0.00% | 0.0% |
| Q4 2022 | $221,660 | -99.9% | 18,154 | -13.9% | 0.00% | 0.0% |
| Q3 2022 | $220,054,000 | -20.3% | 21,078 | -18.0% | 0.00% | 0.0% |
| Q2 2022 | $276,221,000 | +4.6% | 25,695 | +12.5% | 0.00% | 0.0% |
| Q4 2021 | $263,996,000 | -84.2% | 22,837 | -86.9% | 0.00% | -81.8% |
| Q3 2021 | $1,666,098,000 | +608.9% | 174,278 | +614.8% | 0.01% | +450.0% |
| Q2 2021 | $235,023,000 | -35.3% | 24,380 | +55.0% | 0.00% | -33.3% |
| Q4 2020 | $363,317,000 | -9.9% | 15,728 | -44.9% | 0.00% | -25.0% |
| Q3 2020 | $403,126,000 | -52.9% | 28,550 | -49.7% | 0.00% | -60.0% |
| Q2 2020 | $856,061,000 | – | 56,768 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |